Hongli Group Inc. logo

Hongli Group Inc. (HLP)

Market Closed
15 Oct, 08:00 PM
NASDAQ (CM) NASDAQ (CM)
$
3. 00
+0.02
+0.6711%
$
189.84M Market Cap
- P/E Ratio
- Div Yield
242,200 Volume
- Eps
$ 2.98
Previous Close
Investors:
Add Transaction
Day Range
2.97 3.14
Year Range
0.34 3.14
Want to track HLP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

HLP closed today higher at $3, an increase of 0.6711% from yesterday's close, completing a monthly increase of 19.0476% or $0.48. Over the past 12 months, HLP stock gained 188.4615%.
HLP is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.

HLP Chart

People also search for

U.S. Gold Corp.
$ 12.11
+1.4238%
Ioneer Ltd - ADR
$ 2.69
-3.5842%
The Metals Royalty Company Inc.
$ 2.28
-2.9787%
Smith-Midland Corporation
$ 22.83
+2.1934%
Nicola Mining Inc.
$ 5.3
+1.9231%
Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout

Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout

Helus Pharma remains a buy, as HLP003's Phase 3 APPROACH topline data in 4Q26 is the key near-term catalyst. HLP003 targets adjunctive MDD with a differentiated intermittent dosing model; prior Phase 2 data showed a 23-point MADRS reduction and 71% remission at 12 months. HELP's $166.4M cash balance provides 12–14 months runway, but dilution risk persists given high operating outflows and the $100M ATM facility.

Seekingalpha | 4 days ago
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression

Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression

Helus Pharma, formerly known as Cybin NASDAQ: HELP, outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists during TD Cowen's Novel Mechanisms in Neuropsychiatry virtual summit.

Marketbeat | 3 weeks ago
Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst

Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst

Helus Pharma has built a proprietary psychedelic pipeline that currently spans MDD and GAD. The company has two clinical-stage assets and a broader serotonergic discovery platform. Early HLP003 (oral psilocin) and HLP004 (IM DMT) data suggest efficacy and durability when used as adjunctive therapies, although this comes from small trials. Helus is conducting a phase III trial for HLP003, which could validate its clinical profile and reduce the valuation discount relative to peers.

Seekingalpha | 1 month ago

Hongli Group Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
Christopher C. Powers
Christopher C. Powers Farther Finance Advisors, LLC
1,199 $3,021 $3,573.02 $552.02 18.27%

Hongli Group Inc. (HLP) FAQ

What is the stock price today?

The current price is $3.00.

On which exchange is it traded?

Hongli Group Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is HLP.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 189.84M.

Has Hongli Group Inc. ever had a stock split?

No, there has never been a stock split.

Hongli Group Inc. Profile

Metals & Mining Industry
Materials Sector
Jie Liu CEO
NASDAQ (CM) Exchange
G4594M108 CUSIP
CN Country
167 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Hongli Group Inc., founded in 2021, is a prominent entity headquartered in Weifang, China, that operates globally. The company, functioning through its subsidiaries, has carved a niche in the design, customization, manufacturing, and sales of cold roll formed steel profiles. These products find their applications across a broad spectrum of industries such as mining and excavation, construction, agriculture, and transportation. With a geographic reach that extends to the People's Republic of China, South Korea, Japan, the United States, and Sweden, Hongli Group Inc. demonstrates a global footprint in the industrial manufacturing sector. As a subsidiary of Hongli Development Limited, the group leverages synergies within its corporate structure to drive innovation and cater to a diverse client base worldwide.

Products and Services

  • Cold Roll Formed Steel Profiles - Hongli Group Inc. specializes in the production and distribution of high-quality cold roll-formed steel profiles. These profiles are engineered to meet the precise specifications and requirements of machinery and equipment used in various industries. The cold roll forming process ensures superior durability, strength, and performance of the steel profiles, making them suitable for a wide range of industrial applications.
  • Customization Services - Understanding the diverse needs of its clients, Hongli Group Inc. offers customization services that allow for the tailoring of steel profiles according to the specific demands of the machinery or equipment they are intended for. This bespoke approach facilitates optimal compatibility and functionality across different sectors, including mining and excavation, construction, agriculture, and transportation.
  • Global Supply Chain - With its extensive network spanning the People’s Republic of China, South Korea, Japan, the United States, and Sweden, Hongli Group Inc. ensures a reliable and efficient supply of its products and services. This global presence not only broadens the company’s market reach but also enhances its ability to serve clients with speed and efficiency, thereby maintaining high levels of customer satisfaction.

Contact Information

Address: No. 777, Daiyi Road
Phone: 86 53 6218 5222